<DOC>
	<DOCNO>NCT02065986</DOCNO>
	<brief_summary>This study look new way reduce risk catch HIV - Truvada-PrEP . To find whether daily tablet , Truvada , safely reduce risk gay men catch HIV , need large trial half men receive Truvada one year . We know gay men risk HIV interested take Truvada , , whether would willing wait year take . The reason may safe , take Truvada-PrEP may lead increase risk behaviour . This could mean chance catch HIV infection . As well find large trial would possible , study look factor include : - Whether people use PrEP change number partner sex - Whether people use PrEP change often use condom - Whether PrEP lead high rate sexually transmit infection ( STIs ) . This information change sexual activity time one important aspect study , never collect UK . This mean n't know happen people 's sexual activity without PrEP ! In October 2014 interim analysis PROUD study data show pre-exposure prophylaxis ( PrEP ) highly protective HIV gay men men sex men ( MSM ) high risk infection . The PROUD Trial Steering Committee announce participant deferred arm study , yet start PrEP , offer opportunity begin PrEP ahead schedule . As result , change study design offer enrolled participant opportunity access PrEP . All study participant follow study closure October 2016</brief_summary>
	<brief_title>Pre-exposure Option Reducing HIV UK . ( PROUD )</brief_title>
	<detailed_description>Intervention control group : Arm A : Immediate offer Truvada-PrEP Arm B : Deferred ( 12m ) offer Truvada-PrEP Method randomisation : Randomisation perform centrally use computer algorithm base random permuted block stratify site .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Born male gender , age 18 year Previously attend enrol clinic least one occasion Completed screen HIV STIs HIV negative routinely use assay within 4 week prior day randomisation Reported unprotected anal intercourse ( UAI ) one occasion within 90 day prior randomisation Likely , opinion volunteer , UAI next 90 day Willing able comply visit schedule throughout followup period Willing able provide write informed consent An acute viral illness could due HIV seroconversion Any contraindication Truvada accord current package insert Treatment hepatitis B infection indicate ongoing Unlikely , opinion clinician , comply randomise allocation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>Prevention</keyword>
	<keyword>Truvada</keyword>
</DOC>